Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.

British journal of cancer - 29 Oct 2013

Bedognetti D, Spivey T L, Zhao Y, Uccellini L, Tomei S, Dudley M E, Ascierto M L, De Giorgi V, Liu Q, Delogu L G, Sommariva M, Sertoli M R, Simon R, Wang E, Rosenberg S A, Marincola F M

Abstract excerpt

BACKGROUND: Adoptive therapy with tumour-infiltrating lymphocytes (TILs) induces durable complete responses (CR) in ∼20% of patients with metastatic melanoma. The recruitment of T cells through CXCR3/CCR5 chemokine ligands is critical for immune-mediated rejection. We postulated that polymorphism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Interleukin-2
Share to Ligands

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma

Share to Receptors, CCR5

Share to Receptors, CXCR3

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 24129241
DOI: 10.1038/bjc.2013.557
PMCID: PMC3817317

Genes

CCR5
CXCR3
CCL5
CXCL10
CXCL11
CXCL9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24129241-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.PMID 24129241Read ↗

A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in MelanomaSemantic proximity Read ↗

Ligand-receptor pair-based signature score Derived from On-treatment Tumor Specimens Predicts Immune Checkpoint Blockade Response in Metastatic MelanomaSemantic proximity Read ↗

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapySemantic proximity Read ↗

Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.Semantic proximity Read ↗

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignanciesSemantic proximity Read ↗

Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients.Semantic proximity Read ↗

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Semantic proximity Read ↗

Predicting Clinical Outcome through Molecular Profiling in Stage III MelanomaSemantic proximity Read ↗

Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.Semantic proximity Read ↗

Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.Semantic proximity Read ↗

PAX3 and FOXD3 Promote CXCR4 Expression in MelanomaSemantic proximity Read ↗

Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.